Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrating Diabetes Care Into Primary Healthcare Centers in Abuja, Nigeria: A Pilot Study
NCT06907472Active, not recruiting
- Sponsor
- University of Abuja
- Start
- Sep 2025
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial of liquid metformin (Aspargo Labs) and glibenclamide in type 2 diabetes mellitus (T2DM), sponsored by University of Abuja. Primary endpoints: Recruitment rate at 6 months, Adherence to protocol at 6 months and 1 more. Started Sep 2025; status: active, not recruiting.
02
Drugs
liquid metformin (Aspargo Labs)glibenclamide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06907472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06907472.